21-43065263-C-T
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PP5_Very_Strong
The NM_000071.3(CBS):c.676G>A(p.Ala226Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000071.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 15
GnomAD4 exome Data not reliable, filtered out with message: AS_VQSR AF: 7.81e-7 AC: 1AN: 1280734Hom.: 0 Cov.: 27 AF XY: 0.00000157 AC XY: 1AN XY: 638702
GnomAD4 genome Cov.: 15
ClinVar
Submissions by phenotype
Classic homocystinuria Pathogenic:4
- -
The c.676G>A (A226T) was identified in a patients of French Canadian origin in compound heterozygote with c.313C>G (L105V). Clinical characteristics included lens dislocation and elevated fasting homocysteine. Patient had no intellectual impairment and responds to treatment with vitamin B6. -
- -
The c.676G>A;p.(Ala226Thr) missense variant has been observed in affected individual(s) and ClinVar contains an entry for this variant (ClinVar ID: 370382; PMID: 14635102; 21520339; 15365998; 16429402; 9590298) - PS4. Well-established in vitro or in vivo functional studies support a damaging effect on the gene or gene product (PMID: 22267502, 21520339, 20066033, 17540596) - PS3_moderate. The variant is located in a mutational hot spot and/or critical and well-established functional domain (PALP domain) - PM1. This variant is not present in population databases (rs763835246, gnomAD; ABraOM no frequency - http://abraom.ib.usp.br/) - PM2. The p.(Ala226Thr) was detected homozygous state in analyzed sample and was observed in trans with a pathogenic variant (PMID: 21520339; 14635102)PM3_strong. In summary, the currently available evidence indicates that the variant is pathogenic. -
not provided Pathogenic:1
Functional analysis of p.(A226T) variant is associated with significantly reduced enzyme activity (Urreizti et al., 2006; Kruger et al., 2003); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 21520339, 22267502, 14635102, 17540596, 16479318, 31589614, 16429402) -
HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED Pathogenic:1
This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 226 of the CBS protein (p.Ala226Thr). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with homocystinuria (PMID: 14635102, 15365998, 21520339). ClinVar contains an entry for this variant (Variation ID: 370382). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt CBS protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects CBS function (PMID: 9590298, 14635102, 16429402, 17540596, 20066033, 22267502). For these reasons, this variant has been classified as Pathogenic. -
Homocystinuria Pathogenic:1
Variant summary: CBS c.676G>A (p.Ala226Thr) results in a non-conservative amino acid change located in the Pryridoxal-phosphate dependent enzyme domain (IPR001926) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251378 control chromosomes. c.676G>A has been reported in the literature in individuals affected with mild Homocystinuria who are responsive to treatment with Pyridoxine (Vitamin-B6) (example, Kruger_2003, Linnebank_2004, Cozar_2011). These data indicate that the variant may be associated with disease. Several publications report experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in 10%-<30% of normal CBS enzyme activity (example, Kruger_2003, Urreizti_2006). Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic citing overlapping evidence utilized in the context of this evaluation. Based on the evidence outlined above, the variant was classified as likely pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at